1-(3-morpholinophenyl)guanidine | 870782-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-(3-morpholinophenyl)guanidine
• 英文别名: n-(3-Morpholin-4-yl-phenyl)-guanidine；2-(3-morpholin-4-ylphenyl)guanidine
• CAS: 870782-17-5
• 化学式: C₁₁H₁₆N₄O
• 分子量: 220.274
• InChiKey: ZKDPCYZCXFCNEG-UHFFFAOYSA-N

物化性质

• 沸点：
  394.9±52.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  76.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-dimethylamino-1-(2,4-dimethyl-thiazol-5-yl)-propenone 、 1-(3-morpholinophenyl)guanidine 生成 [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-morpholin-4-yl-phenyl)-amine
  参考文献：
  名称：

  [EN] 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  [FR] COMPOSES

  摘要：

  公开号：

  WO2005116025A3
• 作为产物：
  描述：

  氰胺 、 3-(4-吗啉基)苯胺 在 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 以55%的产率得到1-(3-morpholinophenyl)guanidine
  参考文献：
  名称：

  Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

  摘要：

  CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]guinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 mu M, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.08.043

文献信息

• 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
  申请人：Wang Shudong

  公开号：US20090137572A1

  公开（公告）日：2009-05-28

  The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.

  本发明涉及选定的取代嘧啶及其制备方法，含有它们的制药组合物以及它们作为一种或多种蛋白激酶抑制剂的用途，因此可用于治疗增殖性疾病、病毒性疾病和/或其他疾病。
• Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents
  作者：Hao Shao、David W. Foley、Shiliang Huang、Abdullahi Y. Abbas、Frankie Lam、Pavel Gershkovich、Tracey D. Bradshaw、Chris Pepper、Peter M. Fischer、Shudong Wang

  DOI：10.1016/j.ejmech.2021.113244

  日期：2021.3
• Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
  作者：Hao Shao、Shenhua Shi、Shiliang Huang、Alison J. Hole、Abdullahi Y. Abbas、Sonja Baumli、Xiangrui Liu、Frankie Lam、David W. Foley、Peter M. Fischer、Martin Noble、Jane A. Endicott、Chris Pepper、Shudong Wang

  DOI：10.1021/jm301475f

  日期：2013.2.14

  Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the CS-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B-and T-cells.
• 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Cyclacel Limited

  公开号：EP1756098A2

  公开（公告）日：2007-02-28